ESC 365 - Safety and efficacy of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, a meta-analysis of randomized controlled trials

ESC Professional Premium Access

Safety and efficacy of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, a meta-analysis of randomized controlled trials

Session: Chronic heart failure - SGLT2i

Topic: Treatment

Speaker: Doctor A. Awad (Texas City, US)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Ahmed K Awad

University of Texas health sciences, Texas City (United States of America)

0 follower

4 more presentations in this session

Cardiac sodium/hydrogen exchanger (NHE11) as a novel potential target for SGLT2i in heart failure

Speaker: Doctor I. Gimenez Escamilla (Valencia, ES)

SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction

Speaker: Doctor R. Tarantini (Pavia, IT)

The comparison of composite end-points between SGLT-2 inhibitors and placebo in diabetic patients with heart failure with mildly reduced ejection fraction: a meta-analysis of the literature

Speaker: Associate Professor T. Cinar (Istanbul, TR)

SGLT2i uptake among heart failure patients with reduced ejection fraction: ongoing prescriber hesitancy and how to address this.

Speaker: Doctor B. Soh (Waterford, IE)

Access the full session

Chronic heart failure - SGLT2i

Speakers: Doctor A. Awad, Doctor I. Gimenez Escamilla, Doctor R. Tarantini, Associate Professor T. Cinar, Doctor B. Soh

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources